Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J. Harding, Sebastián Mondaca, Jin Won Kim et al.|The Lancet Oncology|2023Cited by 243
Deep Learning on Histologic Slides Accurately Predicts Consensus Molecular Subtypes and Spatial Heterogeneity in Colon CancerJean-Eudes Le Douget, Pierre Laurent‐Puig, Paul Jacob et al.|Modern Pathology|2025Cited by 3